Humanized liver mouse models are constructed by engrafting primary human hepatocytes into immunodeficient mouse livers, thereby reconstructing human-specific metabolic and transport pathways and significantly improving the prediction of pharmacokinetics, drug interactions and hepatotoxicity. These models have been widely applied to MASLD/MASH, fibrosis, hepatocellular carcinoma and viral hepatitis research but remain constrained by the absence of intestinal CYP3A4 expression and functional immune compartments. Emerging approaches, including dual humanization, non-parenchymal cell supplementation, vascularized 3D bioprinting and application of patient-derived hepatocytes, combined with advanced in vitro and computational platforms, further strengthen translational fidelity, reduce R&D attrition and expand the scope for modeling complex metabolism-related diseases.
In multiple myeloma (MM), resistance to B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) treatment continues to limit the
Immune thrombocytopenia (ITP) is an autoimmune disease. Megakaryocyte dysfunction caused by autoimmune response can lead to thrombocytopenia, and the underlying mechanism is still unclear. Single-cell sequencing analysis revealed the heterogeneity of CD34 + HSPCs in bone marrow between ITP patients and healthy groups. Pre-B cell population 1 (pre-B1) showed a significantly lower percentage contribution in ITP groups, and the underlying mechanism involves cell cycle-, cell apoptosis- and cell death-related pathways. The number of eosinophil–basophil mast cell progenitors (EBMPs) is significantly increased in ITP patients and the DEGs of the EBMPs in ITP patients were significantly enriched in immune-related pathways. Further, immunofluorescent staining and Western blot assay highlight C-X-C Motif Chemokine Ligand 8 (CXCL8) and Interferon Regulatory Factor 1 (IRF1) expression were significantly increased in the EBMPs of ITP patients. Furthermore, cell–cell communication analysis identified an impaired LGALS9-CD44 axis between EBMP cells and MkP1 cells in ITP patients, suggesting that targeting the LGALS9-CD44 interaction might hold promise as a therapeutic approach for ITP. Our observations indicate that ITP patients exhibit an elevated proportion of EBMP cells alongside a reduced proportion of pre-B1 cells. CXCL8 and IRF1 are potentially associated with EBMP cell dysfunction and the ITP disease process. Furthermore, the diminished LGALS9-CD44 axis between EBMP and MkP1 cells may contribute to ITP progression, suggesting a direction for future therapeutic investigation.